{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:20:31Z","timestamp":1791181231718,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":349,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"Prometheus Laboratories, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.jim.2012.06.002","type":"journal-article","created":{"date-parts":[[2012,6,10]],"date-time":"2012-06-10T07:52:41Z","timestamp":1339314761000},"page":"177-188","source":"Crossref","is-referenced-by-count":193,"title":["Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum"],"prefix":"10.1016","volume":"382","author":[{"given":"Shui-Long","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Ohrmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Hauenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Salbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukmini","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Lockton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharat","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2012.06.002_bb0005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.coi.2008.06.011","article-title":"Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement","volume":"20","author":"Aarden","year":"2008","journal-title":"Curr. Opin. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.jim.2012.06.002_bb0010","first-page":"S49","article-title":"Limit of blank, limit of detection and limit of quantitation","volume":"29","author":"Armbruster","year":"2008","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.jim.2012.06.002_bb0015","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2012.06.002_bb0020","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jim.2012.06.002_bb0035","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jim.2012.06.002_bb0030","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1080\/00365520802699278","article-title":"Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies","volume":"44","author":"Bendtzen","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.jim.2012.06.002_bb0025","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2036.2012.04997.x","article-title":"The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD","volume":"35","author":"Ben-Horin","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jim.2012.06.002_bb0040","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4161\/mabs.2.3.11782","article-title":"Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies","volume":"2","author":"Brennan","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.jim.2012.06.002_bb0050","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2012.06.002_bb0045","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ibd.21831","article-title":"Therapeutic drug monitoring of biologics for inflammatory bowel disease","volume":"18","author":"Colombel","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jim.2012.06.002_bb0055","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12016-009-8140-3","article-title":"Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases","volume":"38","author":"Emi","year":"2010","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jim.2012.06.002_bb0060","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jim.2012.06.002_bb0065","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ajg.2008.88","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jim.2012.06.002_bb0070","doi-asserted-by":"crossref","first-page":"594","DOI":"10.2174\/138920011795713689","article-title":"Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel disease","volume":"12","author":"Guerra","year":"2011","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jim.2012.06.002_bb0075","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jim.2012.06.002_bb0080","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jim.2012.06.002_bb0085","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00535-011-0474-y","article-title":"Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease","volume":"47","author":"Imaeda","year":"2012","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.jim.2012.06.002_bb0090","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jim.2012.06.002_bb0185","article-title":"Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies","author":"Kopylov","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jim.2012.06.002_bb0100","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2010.01.014","article-title":"Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months","volume":"8","author":"Lichtenstein","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jim.2012.06.002_bb0105","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jim.2012.06.002_bb0110","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/00005176-200405000-00008","article-title":"Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab","volume":"38","author":"Miele","year":"2004","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.jim.2012.06.002_bb0115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1517\/14712598.2012.644271","article-title":"Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?","volume":"12","author":"Miheller","year":"2012","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jim.2012.06.002_bb0120","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ordas","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jim.2012.06.002_bb0125","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2012.06.002_bb0130","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ibd.20177","article-title":"Infliximab dose intensification in Crohn's disease","volume":"13","author":"Regueiro","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jim.2012.06.002_bb0135","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1124\/jpet.104.079277","article-title":"Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys","volume":"313","author":"Rojas","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jim.2012.06.002_bb0140","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jim.2012.06.002_bb0145","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cgh.2010.03.024","article-title":"Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study","volume":"8","author":"Sandborn","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jim.2012.06.002_bb0150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jim.2012.06.002_bb0155","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tibtech.2006.04.001","article-title":"Scientific and regulatory considerations on the immunogenicity of biologics","volume":"24","author":"Shankar","year":"2006","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jim.2012.06.002_bb0160","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1568-9972(03)00048-X","article-title":"The biology of TNF blockade","volume":"2","author":"Suryaprasad","year":"2003","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jim.2012.06.002_bb0190","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/kem261","article-title":"Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies","volume":"46","author":"Svenson","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jim.2012.06.002_bb0195","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2012.06.002_bb0175","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jim.2012.06.002_bb0180","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175912001639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175912001639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T17:23:32Z","timestamp":1542907412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175912001639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":36,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0022175912001639"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2012.06.002","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}